Is natalizumab overshooting its rebound?
Fox
Robert J
RJ
Kappos
Ludwig
L
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D015551:Autoimmunity / Q000187:drug effects / Q000276:immunology; D002490:Central Nervous System / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004334:Drug Administration Schedule; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D039041:Integrin alpha4beta1 / Q000187:drug effects / Q000276:immunology; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D000069442:Natalizumab; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D039041:Integrin alpha4beta1; D000069442:Natalizumab